Andrew D’Silva

Chief Financial Officer, OptimizeRx Corporation

Incoming, effective January 1, 2027. First published here October 28, 2026; built from records as of October 28, 2026.

Andrew D’Silva is due to become Chief Financial Officer of OptimizeRx Corporation on January 1, 2027, according to a filing the company made on August 12, 2026.¹

The filing gives Andrew D’Silva's previous role as Chief Business Officer at OptimizeRx Corporation.¹ Andrew D’Silva already worked at OptimizeRx Corporation when appointed, so the record counts the move as an internal promotion.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
OptimizeRx Corporation (OPRX) Services-Business Services, NEC	Chief Financial Officer	Incoming, effective January 1, 2027	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

January 1, 2027takes effect
OptimizeRx Corporation appointed Andrew D’Silva as Chief Financial Officer, effective January 1, 2027. Profile of Edward Stelmakh.
Andrew D’Silva will become Chief Financial Officer and Ms.
[1] Filing by OptimizeRx Corporation, filed with the SEC on August 12, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, OptimizeRx Corporation. U.S. Securities and Exchange Commission, EDGAR, filed August 12, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Andrew D’Silva wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.